IT & Technology Update

Every woman is at risk of cervical cancer throughout his life. Because of that a vaccine specifically designed to protect women from cervical cancer represents a breakthrough in science and is good news for women everywhere.

Not All the Same Vaccine Technology. Since HPV infection that has ever happened will not trigger the formation of a full natural immunity and the occurrence of re-infection is a common thing to happen. It is great importance if a vaccine that targets a cancer-causing HPV types can stimulate a strong immune response and stable.

Ongoing research has shown that adjuvant system No. 4 (AS04) used in the development of new cervical cancer vaccine for teenage girls and adult women will stimulate a strong immune response and stable compared with the traditional aluminum adjuvant.

Findings from research provided by health experts showed that the vaccine that uses high antibodies showed AS04 against HPV types 16 and 18 (which will be responsible for 70% of cervical cancer in the world), in women vaccinated with a broad age range 10 years up to 55 years and 100% protection for 5.5 years against HPV types 16 and 18 are associated with precancerous lesions that lead to cervical cancer.

The results of several studies conducted by the manufacturer is working with world renowned independent scientists have supported the AS04 provides a higher immune response and increase duration of protection caused by it. In ordinary language, adjuvant is valid as a booster, to help establish a higher immune response and long lasting compared with the same vaccine formulated with aluminum hydroxide only just. Development of a vaccine to prevent cancer is one of the greatest successes achieved by preventive medicine.